158147-63-8

Upstream product

• 638-07-3 ethyl (2-chloroaceto)acetate 
• 212489-66-2 2-amino-4'-isopropoxy-3',4,5-trimethoxybenzophenone 
• 2538-98-9 4-isopropyloxy-3-methoxybenzaldehyde 
• 212490-05-6 2-(4-Isopropoxy-3-methoxy-benzyl)-3-oxo-butyric acid methyl ester 
• 212490-34-1 3-(4-Isopropoxy-3-methoxy-phenyl)-5,6-dimethoxy-1H-indole-2-carboxylic acid methyl ester 
• 212490-20-5 2-[(3,4-Dimethoxy-phenyl)-hydrazono]-3-(4-isopropoxy-3-methoxy-phenyl)-propionic acid methyl ester 

Downstream Products

• 158147-31-0 6,7-dimethoxy-4-(4-isopropoxy-3-methoxyphenyl)-2-(1,2,4-triazol-1-ylmethyl)quinoline-3-carboxylic acid ethyl ester 

Relevant academic research and scientific papers

Studies on disease-modifying antirheumatic drugs. II. Synthesis and activity of the metabolites of ethyl 4-(3,4-dimethoxyphenyl)-6,7-dimethoxy- 2-(1,2,4-triazol-1-ylmethyl)quinoline-3-carboxylate (TAK-603)

The metabolites of ethyl 4-(3,4-dimethoxyphenyl)-6,7-dimethoxy-2- (1,2,4-triazol-1-ylmethyl)quinoline-3-carboxylate (1, TAK-603), which is under clinical evaluation as a new type of disease-modifying antirheumatic drug (DMARD), were prepared to confirm th